Stock Events

Stock Events

Biohaven 

R$23.68
91
+R$0.00+0% Tuesday 14:59

Statistics

Day High
23.68
Day Low
23.68
52W High
23.68
52W Low
19.12
Volume
0
Avg. Volume
0
Mkt Cap
3.58B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-10.56
-8.08
-5.6
-3.12
Expected EPS
-3.1192394310000005
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
2025
0Revenue
-4.06BNet Income

Analyst Ratings

32.94Average Price Target
The highest estimate is 53.90.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
17%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BHVN34.SA. It's not an investment recommendation.
NVIDIA
27
NVDA
Microsoft
22
MSFT
Apple
21
AAPL
Amazon
20
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly offers Emgality, a CGRP antagonist for migraine prevention, directly competing with Biohaven's rimegepant.
AMGEN
AMGN
Mkt Cap233.78B
Amgen's Aimovig, a CGRP receptor blocker for migraine prevention, competes with Biohaven's migraine portfolio.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical's Ajovy, a migraine prevention medication, competes in the same space as Biohaven's treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis, in collaboration with Amgen, markets Aimovig, competing in the migraine prevention market against Biohaven.
Pfizer
PFE
Mkt Cap159.36B
Pfizer competes in various therapeutic areas including CNS disorders, which could put it in competition with Biohaven's neurological focus.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, through its acquisition of Allergan, competes in the migraine market, particularly with Botox and Ubrelvy, a direct competitor to Biohaven's products.
Merck
MRK
Mkt Cap366B
Merck competes in the broader pharmaceutical market, including treatments for conditions that Biohaven targets, potentially competing in future neurological or migraine treatments.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the neuroscience area, including treatments for migraines and other CNS disorders.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline offers products for CNS disorders, including migraine treatments, potentially competing with Biohaven's migraine portfolio.

About

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Show more...
CEO
Vladimir Coric
Employees
274
Country
Virgin Islands (British)
ISIN
BRBHVNBDR001

Listings

XNYS
US
BHVN
SA
BR
BHVN34.SA
BOATS
BOATS
BHVN.BOATS

0 Comments

Share your thoughts

FAQ

What is Biohaven stock price today?▼
The current price of BHVN34.SA is R$23.68 BRL — it has increased by +0% in the past 24 hours. Watch Biohaven stock price performance more closely on the chart.
What is Biohaven stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Sao Paolo Exchange exchange Biohaven stocks are traded under the ticker BHVN34.SA.
What is Biohaven market cap?▼
Today Biohaven has the market capitalization of 3.58B
When is the next Biohaven earnings date?▼
Biohaven is going to release the next earnings report on November 17, 2026.
What were Biohaven earnings last quarter?▼
BHVN34.SA earnings for the last quarter are -4.65 BRL per share, whereas the estimation was -3.89 BRL resulting in a -19.58% surprise. The estimated earnings for the next quarter are N/A BRL per share.
What is Biohaven revenue for the last year?▼
Biohaven revenue for the last year amounts to 0 BRL.
What is Biohaven net income for the last year?▼
BHVN34.SA net income for the last year is -4.06B BRL.
How many employees does Biohaven have?▼
As of September 06, 2026, the company has 274 employees.
In which sector is Biohaven located?▼
Biohaven operates in the Health & Wellness sector.
When did Biohaven complete a stock split?▼
Biohaven has not had any recent stock splits.
Where is Biohaven headquartered?▼
Biohaven is headquartered in NEW HAVEN, Virgin Islands (British).